Cardiology Center of Excellence

Supporting patients living with a rare cardiology condition

Orsini’s Cardiology Center of Excellence launched in 2021 with our first program for homozygous familial hypercholesterolemia (HoFH). Today we support multiple cardiology programs across several rare conditions. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Cardiology Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Home Health Nursing

Access nationwide nursing support for in-home treatment or self-administration training. Our nurses provide clinical support to help patients achieve their treatment goals.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Cardiology Conditions Supported

Explore the rare cardiology conditions Orsini supports below.

About Cryopyrin-Associated Periodic Syndromes (CAPS)

Cryopyrin-associated periodic syndromes are a group of rare, hereditary autoinflammatory disorders. They are inherited in an autosomal dominant pattern, which means that a mutation in 1 copy of the gene is enough to cause the disorder. CAPS are characterized by lifelong recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue. The estimated incidence in the United States is 1 to 2 cases per million people.

CAPS Therapies Supported

Full Name	Arcalyst® (rilonacept)
Drug	Arcalyst
Manufacturer	Kiniksa Pharmaceuticals (UK), Ltd.
Route of Administration	Subcutaneous
Site of Care	Home
Approved Indication	Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older; maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more; and treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older
Disease	Cryopyrin-Associated Periodic Syndromes (CAPS); Deficiency of Interleukin-1 Receptor Antagonist (DIRA); Recurrent Pericarditis (RP)
Therapeutic Area	Cardiology
Enrollment Form Link	Enrollment Form
Phone Number	800-473-3261
Fax Number	877-576-6745
Product Website	arcalyst.com/hcp

About Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

Deficiency of interleukin-1 receptor antagonist (DIRA) is an autoinflammatory disease first reported in 2009 that is characterized by the absence of functional interleukin-1 receptor antagonist (IL-1Ra) protein. Patients with DIRA have life-threatening systemic inflammation with skin and bone involvement. DIRA is a genetic disorder inherited in an autosomal recessive manner, meaning that a mutation in both copies of a gene is needed to cause the disease. DIRA is a very rare disease, with fewer than 50 patients worldwide.

DIRA Therapies Supported

Full Name	Arcalyst® (rilonacept)
Drug	Arcalyst
Manufacturer	Kiniksa Pharmaceuticals (UK), Ltd.
Route of Administration	Subcutaneous
Site of Care	Home
Approved Indication	Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older; maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more; and treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older
Disease	Cryopyrin-Associated Periodic Syndromes (CAPS); Deficiency of Interleukin-1 Receptor Antagonist (DIRA); Recurrent Pericarditis (RP)
Therapeutic Area	Cardiology
Enrollment Form Link	Enrollment Form
Phone Number	800-473-3261
Fax Number	877-576-6745
Product Website	arcalyst.com/hcp

About Hereditary ATTR amyloidosis (hATTR) – Cardiomyopathy (CM)

Hereditary ATTR amyloidosis with cardiomyopathy is a genetic disorder leading to abnormal protein buildup, forming amyloids that accumulate in the heart. This rare condition affects the heart’s structure and function, causing cardiomyopathy. Symptoms include fatigue, shortness of breath, and heart-related issues. As an inherited disorder, it often runs in families. Amyloid deposits can also affect the functioning of the heart, kidneys, eyes, and gastrointestinal tract.

hATTR-CM Therapies Supported

Full Name	Vyndamax® (tafamidis)
Drug	Vyndamax
Manufacturer	Pfizer
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization
Disease	Hereditary ATTR amyloidosis (hATTR) - Cardiomyopathy (CM); Wild type transthyretin amyloid cardiomyopathy (wtATTR-CM)
Therapeutic Area	Cardiology
Enrollment Form Link	Vyndamax Enrollment Form
Phone Number	800-930-2043
Fax Number	877-684-3116
Product Website	vyndamax.pfizerpro.com

Full Name	Vyndaqel® (tafamidis meglumine)
Drug	Vyndaqel
Manufacturer	Pfizer
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization
Disease	Hereditary ATTR amyloidosis (hATTR) - Cardiomyopathy (CM); Wild type transthyretin amyloid cardiomyopathy (wtATTR-CM)
Therapeutic Area	Cardiology
Enrollment Form Link	Vyndaqel Enrollment Form
Phone Number	800-930-2043
Fax Number	877-684-3116
Product Website	vyndamax.pfizerpro.com

About Heterozygous Familial Hypercholesterolemia (HeFH)

Heterozygous familial hypercholesterolemia is an inherited genetic disorder characterized by elevated levels of LDL (“bad”) cholesterol from birth. Unlike the more severe homozygous form, individuals with HeFH have one affected gene, leading to high cholesterol levels and an increased risk of premature cardiovascular disease. Symptoms may include cholesterol deposits in tendons and a family history of early heart disease.

HeFH Therapies Supported

Drug Name	Leqvio® (inclisiran)
Manufacturer	Novartis Pharmaceuticals
Route of Administration	Subcutaneous
Approved Indication	The treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C)
Disease	Primary Hyperlipidemia; Heterozygous Familial Hypercholesterolemia (HeFH)
Therapeutic Area	Cardiology
Enrollment Form Link	Enrollment Form
Phone Numbers	800-372-6153 (Enrollment), 877-515-9670 (Support)
Product Website	leqvio.com

About Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous familial hypercholesterolemia is an ultra-rare, inherited genetic disorder causing extremely high levels of cholesterol in the blood. It affects approximately 1,300 patients in the U.S. Individuals with HoFH have impaired ability to remove LDL (“bad”) cholesterol, leading to severe and premature cardiovascular issues. This condition is more aggressive than typical familial hypercholesterolemia. Symptoms may include early-onset heart disease and cholesterol deposits in tendons.

HoFH Therapies Supported

Full Name	Evkeeza® (evinacumab-dgnb)
Drug	Evkeeza
Manufacturer	Regeneron Pharmaceuticals
Route of Administration	Intravenous
Site of Care	Home or Healthcare Facility
Approved Indication	Adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)
Disease	Homozygous Familial Hypercholesterolemia (HoFH)
Therapeutic Area	Cardiology
Enrollment Form Link	Enrollment Form
Phone Number	800-645-4142
Fax Number	877-473-0199
Product Website	evkeezahcp.com

About Primary Hyperlipidemia

Primary hyperlipidemia is a metabolic disorder characterized by elevated levels of cholesterol and/or triglycerides in the blood, primarily due to genetic factors. This condition disrupts the normal balance of fats, contributing to atherosclerosis and cardiovascular complications. Individuals with Primary Hyperlipidemia may experience no noticeable symptoms, emphasizing the importance of regular lipid screenings for early detection.

Primary Hyperlipidemia Therapies Supported

Drug Name	Leqvio® (inclisiran)
Manufacturer	Novartis Pharmaceuticals
Route of Administration	Subcutaneous
Approved Indication	The treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C)
Disease	Primary Hyperlipidemia; Heterozygous Familial Hypercholesterolemia (HeFH)
Therapeutic Area	Cardiology
Enrollment Form Link	Enrollment Form
Phone Numbers	800-372-6153 (Enrollment), 877-515-9670 (Support)
Product Website	leqvio.com

About Recurrent Pericarditis (RP)

Recurrent pericarditis is a painful autoinflammatory cardiovascular disease that occurs when patients with acute pericarditis experience one or more pericarditis episodes after being symptom-free for 4-6 weeks. The symptoms associated with RP affect patients’ quality of life, can limit physical activities, and lead to frequent emergency department visits and hospitalizations. RP can affect people of all ages and ethnicities, and it is estimated that 40,000 patients in the US seek treatment annually for RP.

RP Therapies Supported

Full Name	Arcalyst® (rilonacept)
Drug	Arcalyst
Manufacturer	Kiniksa Pharmaceuticals (UK), Ltd.
Route of Administration	Subcutaneous
Site of Care	Home
Approved Indication	Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older; maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more; and treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older
Disease	Cryopyrin-Associated Periodic Syndromes (CAPS); Deficiency of Interleukin-1 Receptor Antagonist (DIRA); Recurrent Pericarditis (RP)
Therapeutic Area	Cardiology
Enrollment Form Link	Enrollment Form
Phone Number	800-473-3261
Fax Number	877-576-6745
Product Website	arcalyst.com/hcp